|Awarded On||August 17, 2016|
|Title||A Randomized Clinical Trial Platform with Translational Studies to Overcome Resistance in Triple Negative Breast Cancer|
|Award Mechanism||Multi-Investigator Research Awards (Version 2)|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||William Symmans|
One in six women with breast cancer, and one in three African American women with breast cancer, have triple negative breast cancer (TNBC) – a particularly aggressive type that grows very quickly and lacks the hormone and HER2 receptor targets for some of our most effective treatments. Our best modern chemotherapy is highly effective for nearly half of TNBCs. Indeed, many with TNBC now receive their chemotherapy before surgery (Neoadjuvant Chemotherapy – NACT) so that tumor shrinkage can occur and their surgery can be more conservative. Indeed, those women with TNBC who have complete (or nearly complete) disappearance of their cancer when the pathologist studies the response to NACT will hav...